<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04501757</url>
  </required_header>
  <id_info>
    <org_study_id>20-227</org_study_id>
    <nct_id>NCT04501757</nct_id>
  </id_info>
  <brief_title>Naxitamab and GM-CSF in People With Neuroblastoma</brief_title>
  <official_title>Expanded Access Use of Naxitamab/GM-CSF Immunotherapy for Consolidation of Complete Remission or Relapsed/Refractory High-Risk Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      This is an Expanded Access Program (EAP) that will give the participants access to the drug&#xD;
      naxitamab before it is approved by the FDA. Naxitamab will be combined with&#xD;
      granulocyte-macrophage colony stimulating factor (GM-CSF). Participants in this study will&#xD;
      have high-risk neuroblastoma that either went away completely after treatment (complete&#xD;
      remission) or has come back (relapsed/refractory).&#xD;
&#xD;
      Researchers think the combination of naxitamab and GM-CSF will be effective because naxitamab&#xD;
      and GM-CSF strengthen the immune system's response to cancer cells in different ways.&#xD;
      Naxitamab is an antibody, like the proteins made by the immune system to protect the body&#xD;
      from harm. Naxitamab helps the cells of the immune system to find and attack cancer cells.&#xD;
      GM-CSF is a protein that strengthens the immune system by increasing the number of immune&#xD;
      cells called granulocytes. Granulocytes are white blood cells that fight off cancer cells.&#xD;
      The combination of naxitamab and GM-CSF is a type of immunotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>High-Risk Neuroblastoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Naxitamab/GM-CSF</intervention_name>
    <description>naxitamab/GM-CSF for 5 Cycles</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who are ineligible to participate in study NCT03363373 (IRB# 18-375), will be&#xD;
             considered for treatment under this expanded access protocol.&#xD;
&#xD;
          -  Diagnosis of NB as defined by a) histopathology (confirmed by the MSK Department of&#xD;
             Pathology), or b) BM metastases or MIBG-avid lesion(s) plus high urine catecholamine&#xD;
             levels&#xD;
&#xD;
          -  Patients must have HR-NB (MYCN-amplified stage 2/3/4/4S of any age and&#xD;
             MYCNnonamplified stage 4 in patients greater than 18 months of age).&#xD;
&#xD;
          -  Patients must be in first or greater CR or have refractory or relapsed disease&#xD;
&#xD;
          -  If previously treated with any anti-GD2 mAb, human anti-hu3F8 antibody (HAHA) titer&#xD;
             must be negative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active life-threatening infection&#xD;
&#xD;
          -  Pregnant women or women who are breastfeeding&#xD;
&#xD;
          -  HAHA titer positive&#xD;
&#xD;
          -  History of anaphylaxis CTCAE grade 4 to naxitamab&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Brian Kushner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 30, 2020</study_first_submitted>
  <study_first_submitted_qc>August 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2020</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Remission High-Risk Neuroblastoma</keyword>
  <keyword>Relapsed/Refractory High-Risk Neuroblastoma</keyword>
  <keyword>Naxitamab</keyword>
  <keyword>GM-CSF</keyword>
  <keyword>20-227</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

